Transgene Biotek Board Meeting on Aug 7 to Review Q1 Results

Transgene Biotek Ltd has announced a Board of Directors meeting scheduled for August 7, 2026. The primary agenda items include the consideration and approval of the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026, along with the Limited Review Report. The board will also discuss seeking an extension for the Annual General Meeting for FY 2025-26 and the appointment of the internal auditor for FY 2026-27. The company also informed that the trading window has been closed from July 1, 2026, until 48 hours after the financial results become public.